Acute Hemodynamic Effects of Tolvaptan, a Vasopressin V2 Receptor Blocker, in Patients With Symptomatic Heart Failure and Systolic Dysfunction: An International, Multicenter, Randomized, Placebo-Controlled Trial
J Am Coll Cardiol Udelson et al.
52: 1540
Online Appendix
Files in this Data Supplement:
|